Heron Therapeutics Inc HRTX.OQ HRTX.O is expected to show a rise in quarterly revenue when it reports results on November 4 for the period ending September 30 2025
The Cary North Carolina-based company is expected to report a 19.0% increase in revenue to $39.031 million from $32.81 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Heron Therapeutics Inc is for a loss of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00, about 77.2% above its last closing price of $1.14
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.01 | -0.01 | -0.02 | Missed | -100 |
Mar. 31 2025 | -0.01 | -0.01 | 0.01 | Beat | 249.9 |
Dec. 31 2024 | -0.03 | -0.03 | 0.02 | Beat | 175 |
Sep. 30 2024 | -0.03 | -0.03 | -0.03 | Met | 10 |
Jun. 30 2024 | -0.04 | -0.04 | -0.06 | Missed | -50 |
Mar. 31 2024 | -0.08 | -0.09 | -0.02 | Beat | 77.8 |
Dec. 31 2023 | -0.16 | -0.16 | -0.07 | Beat | 57.2 |
Sep. 30 2023 | -0.29 | -0.29 | -0.17 | Beat | 41.9 |
This summary was machine generated October 31 at 14:21 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments